Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway

Fig. 6

Effect of Andro on VEGF-induced angiogenesis. a HUVECs were exposed to Andro at the indicated doses, and viability was measured by CCK-8 assay. Data were represented as percentage of vehicle-treated control. b The expression level of COX-2 protein was analyzed by Western blot HUVECs treated with the indicated doses of Andro for 48 h, with or without VEGF induction. c-d Effects of Andro on tube formation on Matrigel c at 6 h (Original magnifcation, 50×), and sprouting from modifed human endothelial cell spheroids d at 24 h (Original magnifcation, 200×) . Experiments were performed with or without VEGF and indicated Andro doses. (##p < 0.01, VEGF-treated group vs. Solvent; *P < 0.05, **P < 0.01, Andro treatment vs vehicle control groups)

Back to article page